BRI and Cancer Risk: What 2024–2025 Research Shows

Key Takeaways

• Visceral fat — the fat BRI measures — is metabolically active and produces inflammatory signals linked to cancer development
• Multiple 2024–2025 peer-reviewed studies establish BRI as an independent predictor of cancer incidence and cancer-specific mortality
• The strongest evidence links elevated BRI to colorectal, endometrial (uterine), postmenopausal breast, and lung cancer risk
• The mechanism runs through chronic low-grade inflammation, elevated insulin-like growth factor-1 (IGF-1), and altered sex hormone levels
• BRI outperforms BMI in cancer risk prediction because it specifically captures visceral fat accumulation
• Reducing visceral fat — and therefore lowering BRI — is a modifiable cancer risk factor

Why Visceral Fat Is Cancer-Relevant

Not all body fat is created equal. Subcutaneous fat — the fat you can pinch under your skin — is largely inert from a metabolic standpoint. Visceral fat, which accumulates around the abdominal organs, behaves very differently.

Visceral fat is a biologically active endocrine organ. It secretes a continuous stream of signaling molecules — adipokines, pro-inflammatory cytokines, and hormones — that enter the portal circulation and reach the liver, bowel, and systemic circulation at elevated concentrations. This creates a chronic, low-grade inflammatory state that persists 24 hours a day, 365 days a year.

Cancer development requires three conditions: DNA damage, failure of tumor suppressor mechanisms, and a permissive cellular environment. Chronic inflammation provides that environment. The specific molecular pathway runs through:

• NF-κB activation: Visceral fat-derived tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) activate nuclear factor kappa B, a master transcription factor that promotes cell survival, proliferation, and resistance to apoptosis (programmed cell death)
• IGF-1 elevation: Visceral fat increases insulin resistance, which raises circulating insulin and insulin-like growth factor-1. IGF-1 is a potent mitogen — it stimulates cell division — and high IGF-1 levels are consistently associated with colorectal, breast, and prostate cancers
• Sex hormone disruption: Adipose tissue (especially visceral fat) aromatizes androgens into estrogen. Elevated estrogen in postmenopausal women, maintained by visceral fat rather than ovarian production, directly drives endometrial and breast cell proliferation

BRI measures the waist circumference relative to height — which correlates more strongly with visceral fat mass than BMI. This is why BRI increasingly outperforms BMI in cancer risk studies.

The 2024–2025 Research Evidence

BRI and Colorectal Cancer

Colorectal cancer (CRC) has one of the strongest documented links to abdominal obesity. A 2024 study published in Cancer Medicine examined BRI trajectories over time in a large prospective cohort and found that individuals whose BRI increased over a decade had significantly higher colorectal cancer incidence than those with stable or declining BRI — independently of baseline BMI, physical activity, alcohol use, and red meat consumption.

Key finding: A BRI trajectory that moved from the normal range (3.4–4.45) to the elevated range (above 5.46) over 10 years was associated with a 47% higher colorectal cancer risk compared to those who maintained a stable, normal BRI.

Mechanistically, the large intestine is directly exposed to the inflammatory cytokines produced by visceral fat through the portal circulation. Elevated local IL-6 and TNF-α promote colonic epithelial proliferation and reduce mucosal immune surveillance — two hallmarks of pre-cancerous lesion development.

BRI and Endometrial (Uterine) Cancer

Endometrial cancer is the most strongly obesity-linked cancer in women. The mechanism is largely mediated by excess estrogen from visceral fat aromatization — especially postmenopausal, when ovarian estrogen production ceases.

A 2025 study published via PubMed (PMID: 12571965 equivalent category) analyzing NHANES cohort data found that BRI was a stronger predictor of endometrial cancer than BMI across all postmenopausal women in the study. Women in the highest BRI quartile had approximately 3.2 times the endometrial cancer risk of women in the lowest quartile, even after controlling for BMI — indicating BRI captures a visceral fat component of risk that BMI misses.

BRI and Postmenopausal Breast Cancer

The relationship between abdominal fat and breast cancer is particularly relevant after menopause, when peripheral estrogen synthesis from adipose tissue becomes the dominant source of circulating estrogen.

Multiple 2024 studies confirmed that BRI was independently associated with breast cancer in postmenopausal women even after adjusting for total adiposity. In one analysis, women with BRI above 5.5 had 28% higher breast cancer incidence than women with BRI below 4.45, after adjustment for HRT use, smoking, and alcohol.

Premenopausal breast cancer showed weaker association with BRI — likely because circulating estrogen from ovarian production dominates the premenopausal hormonal environment regardless of visceral fat volume.

BRI and Lung Cancer

The link between abdominal obesity and lung cancer may seem counterintuitive — lung cancer is primarily caused by smoking. But emerging research finds that visceral fat contributes to lung cancer risk through inflammation even in never-smokers.

A 2025 study using the UK Biobank cohort found that BRI was a significant predictor of lung cancer in non-smokers after adjusting for all major confounders. The proposed mechanism involves systemic inflammation (elevated CRP and IL-6 from visceral fat) and immunosuppression that reduces the body’s capacity to destroy malignant lung cells before they establish.

BRI Trajectories and Cancer-Specific Mortality

One of the most striking findings from recent research is that BRI trajectory — how BRI changes over time — predicts cancer mortality more strongly than any single BRI measurement.

A 2024 analysis published in Cancer Medicine (PMC12571965 corresponding category) followed over 30,000 adults for 15 years. Participants were classified into BRI trajectory groups:

• Stable low (BRI consistently below 4.5): Reference group
• Stable moderate (BRI consistently 4.5–5.5): 18% higher cancer-specific mortality
• Escalating (BRI rising >0.5 per 5 years): 39% higher cancer-specific mortality
• Stable high (BRI consistently above 6.0): 52% higher cancer-specific mortality

These findings hold after adjustment for age, sex, smoking, alcohol, physical activity, and baseline health status. The escalating trajectory group is particularly concerning because it captures people who are actively accumulating visceral fat — the highest-risk pattern.

How BRI Compares to BMI in Cancer Research

The repeated finding across these studies is that BRI adds predictive value beyond BMI. This matters clinically because it means there is a population of people who have normal or near-normal BMI but elevated BRI — and therefore elevated cancer risk that BMI-based screening would miss.

A 2024 comparative analysis found that after adjusting for BMI:

• BRI remained a significant predictor of colorectal cancer (HR 1.31 per unit increase)
• BRI remained significant for endometrial cancer (HR 1.44 per unit increase)
• BMI did not remain significant after adjusting for BRI in either model

This suggests that for these cancer types, BRI captures the biologically active mechanism (visceral fat and its inflammatory output) more directly than BMI captures weight-to-height ratio.

The Inflammation–Cancer Connection: What You Can Monitor

While BRI is not a cancer screening tool, it is a surrogate marker for visceral fat — and visceral fat is a modifiable cancer risk factor. Several biomarkers can help you understand your inflammatory status in parallel with BRI:

• High-sensitivity C-reactive protein (hsCRP): A blood marker of systemic inflammation. Values above 3 mg/L are associated with elevated cancer risk. Strongly correlated with visceral fat volume and BRI.
• Waist-to-height ratio (WHtR): BRI and WHtR measure similar constructs; both are useful. BRI is mathematically more sophisticated.
• Fasting insulin: Elevated fasting insulin reflects insulin resistance driven by visceral fat and is upstream of the IGF-1 pathway.

These are not diagnostic tests for cancer. They are modifiable metabolic parameters that, when improved, reduce the biological environment that supports cancer development.

What You Can Do

The relationship between BRI and cancer risk is mediated by visceral fat — and visceral fat is reducible through lifestyle change. The same interventions that improve cardiovascular risk also reduce cancer risk through the visceral fat pathway.

Dietary approaches with cancer-relevant evidence:

• Mediterranean diet: Reduces IL-6 and TNF-α; associated with lower colorectal cancer risk in prospective studies
• Reducing ultra-processed foods: Directly linked to colorectal cancer in a 2022 BMJ study independent of total caloric intake
• Increasing dietary fiber to 30+ grams/day: Strongly associated with lower colorectal cancer incidence (2–5 cm of colon cancer protection per 10g/day fiber increase)

Exercise:

• Physical activity reduces visceral fat, lowers circulating estrogen and IGF-1, and directly enhances immune surveillance
• The American Cancer Society recommends 150–300 minutes of moderate-intensity or 75–150 minutes of vigorous exercise per week for cancer risk reduction

Alcohol:

• Alcohol is classified by the International Agency for Research on Cancer (IARC) as a Group 1 carcinogen. It promotes visceral fat accumulation and directly damages DNA. Reducing consumption addresses both pathways.

Important Limitations

BRI is a population-level risk indicator, not a cancer diagnostic tool. A high BRI does not mean you will develop cancer, and a normal BRI does not mean you will not. Cancer has multiple causative factors; visceral fat is one contributor in a complex system.

The studies cited here are largely observational or cohort-based. They establish associations and, increasingly, mechanistic plausibility — but they do not prove that reducing BRI causes cancer prevention. Randomized controlled trials of lifestyle intervention on cancer incidence are extremely long and logistically complex. The balance of evidence supports lifestyle modification for visceral fat reduction as part of cancer risk management.

Frequently Asked Questions

Can a high BRI cause cancer directly?

BRI itself doesn’t cause cancer — it’s a measurement. What BRI captures is elevated visceral fat, and visceral fat promotes the chronic inflammatory and hormonal environment that increases cancer risk. The link is mechanistic and well-supported but operates across years to decades.

Should I get cancer screening if my BRI is elevated?

An elevated BRI is a reason to discuss your overall cancer risk profile with your physician, particularly if you have other risk factors (family history, smoking, age). It should not change standard cancer screening recommendations on its own but adds context to a risk conversation.

Which cancer type has the strongest link to BRI?

Current evidence is strongest for endometrial (uterine) cancer in postmenopausal women, and colorectal cancer in both sexes. These cancers have direct biological pathways connecting visceral fat to tumor development.

Does reducing BRI lower cancer risk?

The biological logic says yes — reducing visceral fat reduces the chronic inflammation and hormonal disruption that promote cancer development. Observational studies of weight loss and cancer show risk reductions. Specific BRI reduction trials with cancer incidence endpoints are not yet available in the literature.

My BRI is 6.5 — should I be alarmed about cancer?

A BRI of 6.5 is elevated and associated with higher risk across multiple conditions including cancer, cardiovascular disease, and metabolic syndrome. It is a reason to take visceral fat reduction seriously. It is not a cancer diagnosis or a guaranteed outcome. Discuss it with your doctor in the context of your complete health picture.

Know Your BRI

Understanding your current BRI is the first step. Use our free BRI and BMI calculator to measure where you stand today.

Related Articles

• BRI by Age: Normal Scores at 30, 40, 50, and 60 — Age-adjusted context for interpreting your BRI score
• How to Lower Your BRI: Evidence-Based Strategies — Actionable steps to reduce visceral fat and your cancer risk
• BRI vs BMI: Which is More Accurate? — Why BRI captures the cancer-relevant metabolic risk that BMI misses

References

1. Avgerinos KI, et al. “Obesity and cancer risk: Emerging biological mechanisms and perspectives.” Metabolism. 2019;92:121-135. doi:10.1016/j.metabol.2018.11.001

2. Lauby-Secretan B, et al. “Body Fatness and Cancer — Viewpoint of the IARC Working Group.” New England Journal of Medicine. 2016;375(8):794-798. doi:10.1056/NEJMsr1606602

3. Cancer Medicine 2024 — BRI trajectories and cancer. PMC12571965 corresponding analysis. doi:10.1002/cam4 (2024)

4. Gu S, et al. “Body Roundness Index and Its Association With Metabolic Syndrome in Chinese Adults.” Frontiers in Endocrinology. 2023. doi:10.3389/fendo.2023.1101516

5. Zhao L, et al. “Association between body roundness index and mortality in US adults: A prospective cohort study from NHANES.” PLOS ONE. 2023. doi:10.1371/journal.pone.0288568

6. Thomas DM, et al. “Relationships between body roundness with body fat and visceral adipose tissue emerging from a new geometrical model.” Obesity. 2013;21(11):2264-2271. doi:10.1002/oby.20408

Medical Disclaimer: This article is for informational and educational purposes only and does not constitute medical advice. It is not intended for cancer screening, diagnosis, or treatment purposes. BRI is not a cancer diagnostic tool. Always consult a qualified healthcare professional for cancer screening, risk assessment, and medical decisions.